MRKR Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	13 126.00
Średni wolumen	18 037.00
Kapitalizacja rynkowa	37.57M
EPS	$0 ( 2024-03-27 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.65
ATR14	$0.101 (2.39%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Lurier Eliot M	Buy	0
2021-03-16	Eansor Norman David	Buy	14 285	Common Stock
2023-06-06	Eansor Norman David	Buy	8 000	Stock Option (right to buy)
2021-03-25	Eansor Norman David	Buy	7 142	Common Stock
2021-03-25	Eansor Norman David	Sell	14 285	Common Stock

INSIDER POWER
100.00
Last 91 transactions
Buy: 66 397 235 \| Sell: 1 245 536

Marker Therapeutics Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Marker Therapeutics Inc Finanse

Annual	2023
Przychody:	$3.31M
Zysk brutto:	$-7.11M (-214.60 %)
EPS:	$-1.930

FY	2023
Przychody:	$3.31M
Zysk brutto:	$-7.11M (-214.60 %)
EPS:	$-1.930

FY	2022
Przychody:	$9.00M
Zysk brutto:	$5.32M (59.13 %)
EPS:	$-3.58

FY	2021
Przychody:	$1 242.00
Zysk brutto:	$1 241.71 (100.00 %)
EPS:	$-8.90

Financial Reports:

No articles found.

Marker Therapeutics Inc

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.